Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Long-Term DOSE Trial in Multiple Sclerosis
NCT03979456Phase 3Unknown
- Sponsor
- Karolinska Institutet
- Start
- Jul 2018
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Karolinska Institutet. Status: unknown.
02
Drugs
rituximab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT03979456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03979456.